Måseide RJ, Berntorp E, Astermark J, Olsson A, Bruzelius M, Frisk T, Nummi V, Lassila R, Strandberg K, Tjønnfjord GE, Holme PA(2024) Nonneutralizing antibodies in Nordic persons with moderate hemophilia A and B (the MoHem study) Res Pract Thromb Haemost, 8(8), 102611 DOI 10.1016/j.rpth.2024.102611, PubMed 39807249
Reding MT, Lalezari S, Kenet G, Di Minno G, Ducore J, Solms A, Shah A, Holme PA, Poulsen LH, Meijer K, Simpson M, Mancuso ME(2024) Correction: Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review Drugs R D(in press) DOI 10.1007/s40268-024-00494-2, PubMed 39702563
Oldenburg J, Hay C, Peyvandi F, Tagliaferri A, Holme PA, Álvarez-Román MT, Biron-Andréani C, Malmström H, Bystrická L, Lethagen S, A‐SURE Study Group(2024) Superior Prophylactic Effectiveness of a Recombinant FVIIIFc Over Standard Half-Life FVIII in Hemophilia A: A-SURE Study Eur J Haematol, 114(2), 248-257 DOI 10.1111/ejh.14309, PubMed 39434416
